KLOW Peptide Blend: Composition, Laboratory Analysis and Published Research

What KLOW is

KLOW is the trade name for a lyophilised blend of four peptides in one vial: KPV, GHK-Cu, BPC-157 and a component sold as TB-500. The Precise Pep Labs Klow 80 mg vial is labelled as 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV, a 5 : 1 : 1 : 1 ratio by mass. KLOW is a commercial blend name, not a pharmacopoeial substance or an approved medicine, and it has no defined monograph; what is in a vial is whatever the supplier declares and a laboratory can measure.

Two facts shape how the blend should be read. First, the published research concerns the four compounds separately. A PubMed search on November 7, 2026 found no study of the four-component combination (the search is described below), so nothing in this article describes an effect of the blend. Second, a blend has to be analysed component by component: a laboratory must identify each peptide, measure each one's purity and quantify each one's amount. This article explains the four components, what the literature on each actually covers, and what our third-party certificates for KLOW do and do not establish.

Precise Pep Labs sells KLOW for in vitro research use only. Nothing here describes or recommends use in people or animals.

Composition at a glance

The table compares the declared composition with what Axiom Analytics Laboratories measured in the lot currently shipping, PPL-2610-KLOW (certificate AX-2026-2696-CYB5, issued October 15, 2026, two vials).

The four component means printed on the certificate add up to 83.46 mg; the certificate's own total is 83.45 mg. The 0.01 mg difference is rounding: each component mean is printed to two decimals, and the total is calculated from the unrounded vial values. Both figures are as printed.

Equal milligrams are not equal amounts of substance

Because the four molecules differ more than tenfold in mass, the same weight contains very different numbers of molecules. Ten milligrams of KPV (342 Da) contains about fourteen times as many molecules as ten milligrams of thymosin β4 (4,963 Da), and the 52 mg of GHK-Cu (403 Da) is by far the largest molar share of the vial. This is a chemistry point for anyone preparing solutions or comparing studies, not a statement about activity: a blend's label describes mass, and mass ratios are not molar ratios.

The four components

GHK-Cu

GHK is the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma, which binds copper(II) with high affinity; GHK-Cu is that complex ^[8]. The foundational in vitro work showed that GHK-Cu stimulated collagen synthesis in fibroblast cultures, with an effect beginning at picomolar concentrations ^[8]. Much of the later literature, including gene-expression analyses, comes from reviews by GHK's original discoverer and colleagues ^[9]; those reviews are useful maps of the field but are not independent replication. Published human work on GHK-Cu concerns topical cosmetic and wound preparations, not the lyophilised peptide in a research blend.

Because it is a metal complex, GHK-Cu is an identity problem of its own: confirming the peptide's mass does not confirm that copper is bound. The Axiom certificate addresses this with two separate measurements, described in the certificate section below.

BPC-157

BPC-157 (GEPPPGKPADDAGLV) is a synthesised pentadecapeptide; its originators derived the sequence from a larger protein they reported in human gastric juice. Its experimental literature is large but concentrated: most studies are rodent models from one research group, summarised in that group's own reviews ^[6]. An independent in vitro and rat study found that BPC-157 promoted outgrowth, survival and migration of tendon fibroblasts ^[5]. Human data are minimal: a 2025 pilot assessed the safety of intravenous infusion in two participants ^[7], and a 2026 orthopaedic review found human musculoskeletal evidence limited to one small uncontrolled case series ^[12]. No controlled human efficacy trial of BPC-157 was found.

Thymosin β4 and "TB-500"

Thymosin β4 is a naturally occurring 43-residue protein (residues 2–44 of its precursor, with an acetylated N-terminal serine), the main actin-sequestering molecule in most cells ^[1][19]. Its experimental literature covers dermal and corneal wound models; in a rat full-thickness wound model, topical or intraperitoneal thymosin β4 increased re-epithelialisation and collagen deposition ^[2]. Human trials exist only for specific formulations: a phase 1 study of intravenous synthetic thymosin β4 in healthy volunteers ^[17] and a phase 2 trial of thymosin β4 eye drops in severe dry eye ^[18].

"TB-500" is a different matter. In the analytical and anti-doping literature, TB-500 is the name of a product whose key ingredient was identified as Ac-LKKTETQ, the N-acetylated seven-residue fragment 17–23 of thymosin β4, the region associated with actin binding ^[3][4][10]. That fragment has a mass of about 889 Da. The full-length acetylated protein is about 4,963 Da. A 2026 review notes that TB-500 "is a distinct seven amino-acid fragment" of thymosin β4 that is frequently conflated with the full-length protein, and that marketed products raise identity concerns ^[12].

This matters for KLOW because the component labelled "TB-500" on our certificate was confirmed at 4,963.58 Da against a theoretical 4,963.506 Da: the mass of full-length, N-acetylated thymosin β4, not of the 889 Da fragment. Two cautions apply:

• Mass is strong evidence, not proof of sequence. An accurate mass within ± 1 Da of the theoretical value is consistent with full-length thymosin β4; confirming the complete sequence would need fragmentation (MS/MS) or sequencing data, which the certificate does not report.
• The name does not fix the molecule. Products sold as "TB-500" are not necessarily the same substance. Only an identity result on the specific lot says which form a vial contains, and research on the fragment cannot be assumed to describe the full-length protein, or the reverse.

KPV

KPV, the tripeptide Lys-Pro-Val, corresponds to residues 11–13 at the carboxyl end of α-MSH. Its research record, mainly cell-culture NF-κB experiments and mouse colitis models including evidence of uptake through the PepT1 transporter ^[15][16], is covered in detail in our KPV research guide, with the single-compound KPV 5 mg certificate.

Has the four-component combination been studied?

On November 7, 2026 we searched PubMed for BPC-157, thymosin β4 or TB-500, GHK-Cu and KPV together. The search returned no records. Searches for pairs returned:

The one experimental study is Biçer and colleagues (2026), who compared BPC-157, synthetic TB-500 and their combination with controls in a rat Achilles-tendon repair model, using biomechanical testing and histology scores ^[11]. The TB-500 group showed the statistically significant biomechanical difference; the combination group showed lower degeneration scores on one histological scale. That study covers two of KLOW's four components, in one rat model, and does not report which molecular form of "TB-500" was used.

Two independent 2026 reviews reach similar conclusions about the wider field: most published work on these peptides is preclinical, human studies are few and weakly controlled, and products sold under these names raise concerns about identity, purity and consistency ^[12][13].

The conclusion is limited to PubMed on that date. It does not rule out unpublished work, conference abstracts or studies in other databases. Within that scope, no published study has tested the KLOW combination, and findings for individual components cannot be added together to describe it: blends can change stability, solubility and analytical behaviour, and no data exist on how these four compounds behave together.

Reading a KLOW certificate: four separate questions

A single-compound certificate answers three questions: is it the right molecule, how pure is it, and how much is there. A four-component blend needs each answered four times, plus a fourth question about the mixture. Article 1 explains the fields on a certificate in general; here is how the Axiom report for lot PPL-2610-KLOW answers them.

Identity of each component

Axiom reports an accurate-mass match for each declared component by LC-MS, with every observed mass within ± 1 Da of its theoretical value in both vials: GHK-Cu 402.825 Da (theoretical 402.92), BPC-157 1,419.438 Da (1,419.556), TB-500 4,963.58 Da (4,963.506) and KPV 342.426 Da (342.44). For GHK-Cu it adds a separate measurement of the intact copper complex by HILIC-ESI-MS, matched against a qualified reference standard in the same run, with the natural copper isotope pattern confirmed. That second measurement is what shows the copper is bound, which a peptide mass alone cannot. Mass spectrometry coupled to liquid chromatography is the technique regulators expect for peptide identity ^[14].

Purity of each component, and what "purity of a blend" means

Each component's purity was measured against the same locked criterion, at least 99.25 area %, by HILIC with charged-aerosol detection plus reversed-phase HPLC at 214 nm. The four component means are 99.91 % (GHK-Cu), 99.6 % (BPC-157), 99.54 % (TB-500) and 99.62 % (KPV).

The certificate's headline purity, 99.67 %, is not a fifth measurement of the whole mixture. The certificate does not state how it is derived, but the arithmetic is unambiguous: it equals the simple average of the four component purities. The per-vial headline figures confirm this, since vial A's 99.72 % is the average of its four component results (99.86, 99.5, 99.64, 99.88) and vial B's 99.61 % is the average of its four (99.95, 99.7, 99.43, 99.36). An arithmetic mean counts each component equally, whatever its share of the vial, so it summarises four separate results rather than measuring the mixture as a whole; it also sits above the lowest component result, 99.54 % for TB-500.

A blend has no single chromatographic purity. The useful statement is the per-component one: every component met its own 99.25 % criterion. Article 2 explains why purity percentages and milligram figures answer different questions.

Quantity of each component and of the total

Net content was measured by quantitative HPLC against reference standards for each component, with acceptance ranges of 45–55 mg for GHK-Cu and 9–11 mg for each 10 mg component. All four fell inside their ranges, and the total mean was 83.45 mg against an 80 mg target with a ± 10 % tolerance. Axiom also reports the observed ratio, 4.94 : 1.00 : 0.99 : 0.99 for GHK-Cu : BPC-157 : TB-500 : KPV against the declared 5 : 1 : 1 : 1, and container-to-container coefficients of variation between 0.27 % (KPV) and 3.29 % (BPC-157), which describe how consistent the two vials were.

Other screens on the certificate

The same report includes bacterial endotoxin of 0.094 EU/mg against Axiom's house limit of 0.5 EU/mg using the USP kinetic chromogenic LAL method, a rapid PCR screen for microbial DNA, an elemental impurities screen referenced to ICH Q3D, and a targeted fentanyl-analogue screen, all reported as PASS. Axiom defines PASS narrowly: the result met the specification shown, and it "does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use". Axiom also labels the PCR screen as a research screen that is neither a microbial count nor a sterility determination, and states that unless it sampled the lot itself, it does not attest that the two vials represent the wider lot.

Current and historical KLOW certificates

Our COA Library keeps an earlier KLOW certificate from Kovera Labs, report KVR-2026-84DDA5, for a previous lot with no batch number on the certificate. The certificate's printed certification date is July 20, 2026; it was added to our COA Library on August 5, 2026, which is the date the library lists it under. Neither date is the date the laboratory tested the sample. It is historical evidence and does not describe the lot currently shipping.

The two certificates describe different lots, certified about three months apart by different laboratories, so the numbers are not a disagreement. The more important difference is what each format can show: the Axiom report gives a purity and an identity for every component, while the Kovera report's single blend-average purity cannot show whether one component was less pure than the others.

KLOW and GLOW

GLOW is KLOW minus KPV. Our Glow 70 mg vial is labelled as 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500; Klow 80 mg adds 10 mg KPV.

That is the whole verified difference. No published study compares the two blends, and none tests either one, so there is no evidence-based basis for describing one as suited to a different purpose than the other. Each product's certificates are in the COA Library.

Limitations and open questions

• No published study of the blend was found in PubMed on November 7, 2026; one rat study covers two of the four components.
• Uneven component literatures. BPC-157 research is mostly rodent work from one group; GHK-Cu's mechanistic literature leans on its originator's reviews; thymosin β4 has human trials only for specific formulations; KPV's in vivo work is mostly mouse colitis.
• "TB-500" is ambiguous across the market. The term has been used for both the seven-residue fragment and the full-length protein, and results for one cannot be applied to the other.
• Mass confirms identity, not full sequence. Accurate-mass results are strong evidence; sequence-level confirmation is not on either certificate.
• No interaction or stability data. Nothing published describes how these four compounds behave together in one vial or in solution.
• Certificates describe the vials tested. Both laboratories state that results apply to the submitted sample.

Where to find KLOW certificates

Both KLOW certificates, the current Axiom report and the earlier Kovera report, are in the COA Library under Klow 80 mg, and the product page links the certificate for the lot currently shipping, identified by its inventory batch number. Component compounds sold separately have their own certificates, including BPC-157 10 mg, GHK-Cu 50 mg and KPV 5 mg. Where a lot on a vial does not appear in the library, contact us with the lot number.